Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Progressive pulmonary fibrosis (PPF) can advance on its own even when the underlying disease is well-managed — and about 30% of fibrotic lung disease patients follow this course. New antifibrotic drugs like nintedanib and the newly approved nerandomilast are expanding treatment options, but early recognition and multidisciplinary care are critical to preserving lung function before it's too late.
Here's a frustrating clinical reality: a patient's rheumatoid arthritis or systemic sclerosis can be perfectly managed, yet their lungs continue to deteriorate. That's the hallmark of progressive pulmonary fibrosis (PPF) — a phenotype where tissue remodeling becomes self-sustaining, independent of the original disease trigger. Once fibrogenesis kicks in, it can run on autopilot, making standard immunosuppressive therapy insufficient to stop the decline.
Catching PPF early is key. Guidelines from major respiratory societies define PPF by at least two of three criteria within a year: worsening symptoms, a significant drop in lung function (FVC ≥5% or DLCO ≥10%), or CT scan progression. Experts recommend follow-up every 3–6 months in the first two years — not waiting the full 12 months to act. When PPF is confirmed, treatment shifts toward antifibrotic agents, sometimes layered on top of immunosuppressives.
Key Takeaways:
Why it matters: PPF affects roughly 30% of fibrotic ILD patients and is a leading cause of death in conditions like systemic sclerosis. With new antifibrotic options emerging, the window for intervention matters enormously — but access gaps in public health systems mean many patients still face significant barriers to receiving these therapies.
